AGF Management Ltd. Has $3.19 Million Stock Holdings in Cencora, Inc. $COR

AGF Management Ltd. trimmed its position in Cencora, Inc. (NYSE:COR) by 17.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,652 shares of the company’s stock after selling 2,226 shares during the quarter. AGF Management Ltd.’s holdings in Cencora were worth $3,194,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. boosted its stake in shares of Cencora by 42.1% in the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after purchasing an additional 1,364,433 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Cencora by 4,459.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after buying an additional 975,362 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Cencora by 8.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after acquiring an additional 787,858 shares during the last quarter. Nuveen LLC acquired a new stake in Cencora during the 1st quarter worth $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its position in shares of Cencora by 144.4% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock valued at $206,641,000 after acquiring an additional 439,008 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Trading Up 0.1%

COR opened at $360.56 on Monday. The stock has a market capitalization of $69.90 billion, a P/E ratio of 37.09, a P/E/G ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $364.36. The firm’s fifty day simple moving average is $314.27 and its 200 day simple moving average is $299.54. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is 30.19%.

Analysts Set New Price Targets

COR has been the subject of a number of analyst reports. Mizuho lifted their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday. Robert W. Baird boosted their target price on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research report on Thursday. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Finally, Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.50.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 41,544 shares of company stock worth $12,230,941 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.